Get the Stockscreener App
9.955
0.20%
0.025
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Viatris Inc stock is traded at $9.955, with a volume of 1.50M.
It is up +0.20% in the last 24 hours and up +3.65% over the past month.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
See More
Previous Close:
$9.93
Open:
$10.02
24h Volume:
1.50M
Relative Volume:
0.16
Market Cap:
$11.61B
Revenue:
$14.33B
Net Income/Loss:
$-3.79B
P/E Ratio:
-3.1404
EPS:
-3.17
Net Cash Flow:
$1.84B
1W Performance:
-0.20%
1M Performance:
+3.65%
6M Performance:
+33.02%
1Y Performance:
-15.96%
1-Day Range:
$9.9201
$10.17
1-Week Range:
$9.69
$10.17
52-Week Range:
$6.85
$13.55
Viatris Inc Stock (VTRS) Company Profile
Name
Viatris Inc
Sector
Phone
(724) 514-1465
Address
1000 MYLAN BOULEVARD, CANONSBURG
Compare VTRS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VTRS
Viatris Inc
|
9.955 | 11.58B | 14.33B | -3.79B | 1.84B | -3.17 |
|
ZTS
Zoetis Inc
|
143.24 | 63.58B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.87 | 43.58B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.175 | 40.83B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
19.86 | 23.07B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
438.56 | 19.61B | 3.08B | 1.24B | 1.07B | 25.61 |
Viatris Inc Stock (VTRS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-06-25 | Initiated | Goldman | Neutral |
| Jul-19-24 | Resumed | Jefferies | Buy |
| Oct-23-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-23-23 | Downgrade | Barclays | Equal Weight → Underweight |
| Apr-24-23 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-17-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jan-27-23 | Upgrade | Jefferies | Hold → Buy |
| Nov-10-22 | Upgrade | UBS | Sell → Neutral |
| Nov-08-22 | Upgrade | Piper Sandler | Underweight → Neutral |
| Oct-21-22 | Resumed | Jefferies | Hold |
| Jun-14-22 | Initiated | UBS | Sell |
| May-10-22 | Downgrade | Piper Sandler | Neutral → Underweight |
| Mar-01-22 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-01-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jun-15-21 | Initiated | Citigroup | Neutral |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Mar-08-21 | Downgrade | Goldman | Buy → Neutral |
| Mar-02-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-26-21 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jan-05-21 | Initiated | Argus | Hold |
| Dec-14-20 | Initiated | Bernstein | Mkt Perform |
View All
Viatris Inc Stock (VTRS) Latest News
Will Viatris Inc. stock benefit from upcoming earnings reportsMarket Performance Summary & Weekly High Conviction Ideas - newser.com
Is Viatris Inc. stock a good choice for value investorsJuly 2025 Sentiment & Community Verified Trade Alerts - newser.com
Can trapped investors hope for a rebound in Viatris Inc.Market Movement Recap & Step-by-Step Trade Execution Guides - newser.com
Pattern recognition hints at Viatris Inc. upsideJuly 2025 Market Mood & Proven Capital Preservation Methods - newser.com
Nov 11 & 18: Viatris Fireside Chats at UBS and Jefferies — Live webcasts and archived access - Stock Titan
Viatris Inc. (VTRS) Stock Analysis: Exploring a 17.34% Potential Upside Amidst Healthcare Sector Dynamics - DirectorsTalk Interviews
Developing predictive dashboards with Viatris Inc. data2025 Market Overview & Long-Term Growth Portfolio Plans - newser.com
Viatris Inc. Stock Falls Friday, Still Outperforms Market - 富途牛牛
Kotak Alts-backed Matrix Pharma buys bulk-drugs maker - VCCircle
Teva, Viatris On Investor Watch As White House Spares Generic Drugs From Tariffs - Benzinga
Viatris Named to Forbes' Annual List of the World's Best Employers for the Fifth Year in a Row - PR Newswire
Viatris shares break six-session winning streak - MSN
Viatris Inc. (VTRS) Investor Outlook: Navigating a 12.15% Potential Upside Amidst Healthcare Challenges - DirectorsTalk Interviews
What analysts say about Viatris Inc stockRSI Overbought/Oversold & Small Entry Cost Trading - earlytimes.in
Morocco fines Viatris 7.58 million dirhams over Mylan-Pfizer merger - MSN
Allergy Treatment Global Market Forecast and Company Analysis Report 2025-2033 Featuring AbbVie, ALK - PharmiWeb.com
Viatris to Report Third Quarter 2025 Financial Results on November 6, 2025 - BioSpace
The Importance of a Global, Resilient Supply Chain to Access - CSRwire
Relative strength of Viatris Inc. in sector analysisProduct Launch & Reliable Price Action Trade Plans - newser.com
Acute Social Anxiety Disorder Market on Track for Major Expansion by 2034, According to DelveInsight | GlaxoSmithKline Plc, Viatris Inc, Johnson & Johnson, Novartis AG, Pfizer Inc, AstraZeneca Plc - Barchart.com
Pharmaceutical Giant Viatris Schedules Q3 2025 Financial Results and Investor Conference Call for November 6 - Stock Titan
Will Viatris Inc. stock continue dividend increasesMarket Performance Summary & Risk Controlled Swing Alerts - newser.com
Viatris Inc. (VTRS) Stock Analysis: Exploring a Potential 20% Upside Amid High Dividend Yield - DirectorsTalk Interviews
Quantitative breakdown of Viatris Inc. recent moveJuly 2025 Gainers & Low Drawdown Momentum Trade Ideas - newser.com
Levi & Korsinsky Notifies Viatris Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineVTRS - 2822news.com
What drives Viatris Inc stock priceBear Market Strategies & Free Unstoppable Trading Performance - earlytimes.in
What drives Viatris Inc VIA stock priceStock Buyback Updates & Build Wealth With Expert Timing Advice - earlytimes.in
What analysts say about Viatris Inc VIA stockCandlestick Trading Patterns & Identify Breakout Stocks - earlytimes.in
Viatris Inc VIA Stock Analysis and ForecastFederal Reserve Announcements & Explosive Profit Growth - Early Times
Is Viatris Stock Underperforming the Nasdaq? - MSN
Viatris: Indore Plant Could Boost 2026 Numbers (NASDAQ:VTRS) - Seeking Alpha
Viatris Nixes Biogen's Extra 1-Year Protection Over MS Drug - Law360
Viatris Inc. (VTRS) Gains FDA Approval for First Generic Iron Sucrose Injection - Insider Monkey
How Viatris’ (VTRS) Removal from the FTSE All-World Index Could Affect Investor Sentiment - Sahm
Viatris Inc.(NasdaqGS: VTRS) dropped from FTSE All-World Index - MarketScreener
Viatris (VTRS): Evaluating Valuation Following FDA Nod for Generic Iron Sucrose and Pipeline Progress - Sahm
Street Watch: Is Viatris Inc a defensive stock2025 Technical Patterns & Weekly Stock Performance Updates - خودرو بانک
Fundamentals Check: Is now the right time to enter Viatris IncJuly 2025 Spike Watch & Target Return Focused Picks - khodrobank.com
Will Viatris Inc. see short term momentum2025 Major Catalysts & Growth Oriented Trading Recommendations - newser.com
Trading Recap: Can Viatris Inc. withstand a market correctionInsider Selling & Precise Trade Entry Recommendations - khodrobank.com
Forecast Cut: How do insiders feel about Viatris IncWeekly Stock Report & Long Hold Capital Preservation Tips - خودرو بانک
Short Covering: Will Viatris Inc stock hit new highs in YEAROil Prices & Free Verified High Yield Trade Plans - khodrobank.com
Viatris pulls generic for Teva’s Trisenox in EU - MSN
VIX Spike: Can Viatris Inc ride the EV waveRisk Management & Reliable Momentum Entry Alerts - خودرو بانک
Viatris Inc. (VTRS) Enters $515M IV Iron Market With FDA Green Light - MSN
Viatris (VTRS) Recovers Slightly But Struggles Amid Market Conce - GuruFocus
Viatris rises after a steep seven-day slide - MSN
Day 7 of Loss Streak for Viatris Stock with -9% Return (vs. -20% YTD) [9/16/2025] - Trefis
Institution Moves: Can Viatris Inc ride the EV waveLong Setup & Daily Momentum Trading Reports - خودرو بانک
Viatris Inc Stock (VTRS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.36%
0.27%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):